SCHEDULE: Suvretta Capital Exits Sutro Biopharma Stake

Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have reported a 0% beneficial ownership in Sutro Biopharma, Inc., indicating a full divestment or reduction below the 5% reporting threshold.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an Amendment No. 5 to their Schedule 13G for Sutro Biopharma, Inc.
• The reporting persons now beneficially own 0 shares of Sutro Biopharma's Common Stock, representing 0% of the class.
• This indicates a complete divestment of their previously reported stake or a reduction below the 5% reporting threshold.
• The event date requiring this filing was December 31, 2025.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of Sutro Biopharma.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal for Sutro Biopharma, as a significant institutional investor has fully divested its stake, potentially indicating a loss of confidence or a shift in investment strategy.

Negatives

• A significant institutional investor, Suvretta Capital Management, LLC, along with its affiliates, has fully divested its stake in Sutro Biopharma, Inc.
• This divestment could be interpreted by the market as a loss of confidence in the company's future prospects by a sophisticated investor.

Risks

• The market may react negatively to the news of a major institutional investor exiting its position, potentially leading to downward pressure on Sutro Biopharma's stock price.
• A reduction in institutional ownership can sometimes reduce liquidity or investor interest in the stock.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that institutional divestments, particularly a complete exit by a significant fund, can signal a change in investment thesis or a re-evaluation of the company's prospects relative to its peers within the biopharma sector. Such moves often prompt other investors to scrutinize the company's fundamentals more closely.

Stakeholder Impact

• Shareholders may experience negative sentiment and potential downward pressure on stock price due to the institutional divestment.
• Potential investors might view the company with increased caution given the exit of a major institutional holder.

Key Dates

Recommendation

The complete divestment by a significant institutional investor like Suvretta Capital Management, LLC removes a key institutional backing and could signal a lack of conviction in Sutro Biopharma's future performance. While not a direct operational update, this ownership change warrants a cautious 'hold' stance for current or prospective investors, prompting further due diligence into the company's fundamentals.

Keywords

Sutro Biopharma, Suvretta Capital Management, Schedule 13G, beneficial ownership, institutional investment, divestment